Utility of gonadotropin-releasing hormone agonists for fertility preservation in women receiving chemotherapy: pros and cons

Fertile Battle

Go to the profile of Fertility and Sterility
Fertility and Sterility
Editorial Office, American Society for Reproductive Medicine
Published
Like Comment
Related Content

VOLUME 114, ISSUE 4, P725-738

Authors:

Marie-Madeleine Dolmans, M.D., Ph.D., Hugh S. Taylor, M.D., Kenny A. Rodriguez-Wallberg, M.D., Ph.D., Zeev Blumenfeld, M.D., Matteo Lambertini, M.D., Ph.D., Michael von Wolff, M.D., Jacques Donnez, M.D., Ph.D.

Abstract:

Con: GnRH-a should not be used for fertility preservation in women receiving chemotherapy

Pro: PRO: GnRH-a should be used for fertility preservation in women receiving chemotherapy

Read the full text here. 

Should GnRH-a be used for fertility preservation in women receiving chemotherapy?
Yes
No
Created with Survey maker

Go to the profile of Fertility and Sterility

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.